TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06128447: A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus),

Sponsor: Zero Point Five Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT06128447 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06128447 Rescue Dossier →